Skip to main content

AGILENT TECHNOLOGIES, INC.

corporate_fare Company Profile

AGILENT TECHNOLOGIES, INC.

A·NYSE·Life Sciences·CIK 0001090872

Agilent Technologies, Inc., incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics, and applied markets. The company provides application-focused solutions, including instruments, software, services, and consumables, for the entire laboratory workflow. In November 2024, Agilent reorganized its structure into three business segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers specialty contract development and manufacturing services for pharmaceutical customers. It also provides solutions, including reagents, instruments, software, and consumables, for clinical and life sciences research, enabling customers to analyze samples at the cellular and molecular level. The Agilent CrossLab segment delivers extensive services and consumables, along with software and laboratory automation solutions, across the entire lab. These offerings are designed to improve customer outcomes and serve a broad range of customer needs across various end-markets and applications. The Applied Markets segment provides application-focused solutions, including instruments and software, that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products. Agilent also conducts centralized order fulfillment and supply chain operations for its businesses through its order fulfillment and supply chain organization (OFS).

AGILENT TECHNOLOGIES, INC. (NYSE:A) is a publicly traded company in the Life Sciences sector. Wiseek monitors A SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Agilent Partners with OpenAI, BCG to Drive AI-Powered Scientific Innovation
  • FDA Expands Agilent's Cancer Test Approval to Four New Tumor Types
  • Agilent Reports Strong Q2 2026 Results with Double-Digit Revenue Growth and Significant EPS Increase
  • Agilent Reports Strong Q2 Results, Raises Full-Year Revenue and EPS Guidance
  • Agilent boosts 2026 profit outlook after Q2 earnings and revenue beat

Financial Snapshot

Fiscal year ended October 31, 2025
Revenue
$6.95B
Net Income
$1.3B
Diluted EPS
$4.57
Op. Cash Flow
$1.56B
Free Cash Flow
$1.15B
Gross Profit
$3.64B
Operating Income
$1.48B
Cash & Equivalents
$1.79B
Total Debt
$3.35B
Debt / Equity
0.50×
Net Margin
18.8%
Shares Outstanding
283.05M sh
Source: 10-K · filed 2025-12-19 · accession 0001090872-25-000087
Browse all tickers starting with A →
$129.75 -0.09% today
52-week range · as of 2026-06-01 $108.35 – $160.27
Market cap
$36.67B
Volume
2.3M (0.9× avg)
3-mo avg 2.5M
Live data · 2026-06-14 05:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed A - Latest Insights

A
Jun 03, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $134.92
Real-time Price: $129.75 info
Change: -$5.17 (-4%) info
Market Cap: $36.671B info
A
Jun 02, 2026, 4:43 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $134.93
Real-time Price: $129.75 info
Change: -$5.18 (-4%) info
Market Cap: $36.671B info
A
Jun 01, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $135.98
Real-time Price: $129.75 info
Change: -$6.23 (-5%) info
Market Cap: $36.671B info
A
May 27, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $122.14
Real-time Price: $129.75 info
Change: +$7.61 (+6%) info
Market Cap: $36.671B info
A
May 27, 2026, 4:05 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $117.57
Real-time Price: $129.75 info
Change: +$12.18 (+10%) info
Market Cap: $36.671B info
A
Mar 26, 2026, 8:49 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $113.32
Real-time Price: $129.75 info
Change: +$16.43 (+14%) info
Market Cap: $36.671B info
A
Mar 20, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $111.30
Real-time Price: $129.75 info
Change: +$18.45 (+17%) info
Market Cap: $36.671B info
A
Mar 10, 2026, 5:48 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $116.64
Real-time Price: $129.75 info
Change: +$13.11 (+11%) info
Market Cap: $36.671B info
A
Mar 09, 2026, 3:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $116.41
Real-time Price: $129.75 info
Change: +$13.34 (+11%) info
Market Cap: $36.671B info
A
Feb 25, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $121.31
Real-time Price: $129.75 info
Change: +$8.44 (+7%) info
Market Cap: $36.671B info
A
Jan 23, 2026, 7:00 AM EST
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $138.63
Real-time Price: $129.75 info
Change: -$8.88 (-6%) info
Market Cap: $36.671B info